This Cognex Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

• Deutsche Bank analyst Bryan Keane downgraded the rating for Marqeta, Inc. MQ from Buy to Hold and lowered the price target from $9 to $4. Marqeta shares closed at $5.95 on Monday. See how other analysts view this stock.
• Truist Securities analyst Jamie Cook downgraded Cognex Corporation CGNX from Buy to Hold and slashed the price target from $46 to $43. Cognex shares closed at $40.85 on Monday. See how other analysts view this stock.
• JMP Securities analyst Reni Benjamin downgraded the rating for Sana Biotechnology, Inc. SANA from Market Outperform to Market Perform. Sana Biotechnology shares closed at $3.76 on Monday. See how other analysts view this stock.
• JP Morgan analyst Tessa Romero downgraded Neumora Therapeutics, Inc. NMRA from Overweight to Neutral and lowered the price target from $18 to $15. Neumora Therapeutics shares closed at $11.71 on Monday. See how other analysts view this stock.
• Leerink Partners analyst Christopher Liu downgraded the rating for IDEAYA Biosciences, Inc. IDYA from Outperform to Market Perform and lowered the price target from $41 to $27. IDEAYA Biosciences shares closed at $30.00 on Monday. See how other analysts view this stock.

Considering buying CGNX stock? Here’s what analysts think:

Read This Next:

• Top 3 Health Care Stocks You’ll Regret Missing In November